Abstracts Archive - Page 1665 of 2425 - ACR Meeting Abstracts

Abstract Number: 2895 • 2015 ACR/ARHP Annual Meeting
Intraarticular Sacroiliac Corticosteroid Injections in Ankylosing Spondylitis
Seunghun Lee¹, Sung Won Lee², Yoonah Song¹, Il-Hoon Sung³ and Tae-Hwan Kim², ¹Department of Radiology, Hanyang University College of Medicine, Seoul Hospital, Seoul, South Korea, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Department of Orthopaedic Surgery, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease which involves axial skeleton. NSAIDs are drug of choice and biologic disease-modifying anti-rheumatic drugs (DMARDs) are strongly…
Abstract Number: 2896 • 2015 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Efficacy and Safety Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Dominique Baeten¹, Jurgen Braun², Joachim Sieper³, Maxime Dougados⁴, Atul A. Deodhar⁵, Xenofon Baraliakos⁶, Brian Porter⁷, Yankun Gong⁸ and Hanno Richards⁹, ¹1Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, Herne, Germany, ³University Clinic Benjamin Franklin, Berlin, Germany, ⁴Paris-Descartes University, Paris, France, ⁵Oregon Health and Sciences University, Portland, OR, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Beijing Novartis Pharma Co. Ltd., Beijing, China, ⁹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, an anti–interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) over 52 weeks (wks) in the randomized, double-blind, placebo (PBO)-controlled,…
Abstract Number: 2897 • 2015 ACR/ARHP Annual Meeting
Predictors of Organ Damage Progression and Impact on Health-Related Quality of Life in Systemic Lupus Erythematosus
Alexandra Legge¹, Steve Doucette² and John G. Hanly³, ¹Department of Medicine, Dalhousie University, Halifax, NS, Canada, ²Dalhousie University and Capital Health, Halifax, NS, Canada, ³Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada
Background/Purpose: To describe cumulative organ damage in a longitudinal cohort of SLE patients and to evaluate the impact of key disease-related factors, medical therapies, demographic…
Abstract Number: 2898 • 2015 ACR/ARHP Annual Meeting
Erythrocytes, Acanthocytes, and Proteins in Urine Reflect Lupus Nephritis Histology
Marco Ulises Martinez-Martinez¹, Lilia Llamazares-Azuara², David Martínez-Galla³, Francisco Valadez-Castillo⁴, Peter Mandeville⁴, Jaime Antonio Borjas García⁵ and Carlos Abud-Mendoza¹, ¹Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ²Laboratorio Renal, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ³Patología, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁴Faculty of Medicine, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁵Regional Unit of Rheumatology and Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico
Background/Purpose: Hematuria in lupus nephritis (LN) is secondary to the passage of red blood cells (RBCs) through glomerular abnormalities. Dysmorphic RBCs are associated with glomerulonephritis,…
Abstract Number: 2899 • 2015 ACR/ARHP Annual Meeting
Mortality Related to Pediatric Systemic Lupus Erythematosus: A Multiple Cause-of-Death Analysis in France
laurent chiche¹, sarah malaekah², alexandre belot³, Brigitte Bader-Meunier⁴, gregoire rey⁵, Noémie Jourde-Chiche Sr.⁶ and mireille eb⁵, ¹internal medicine, Hopital Europeen, Marseille, France, ²pediatry, CHU Lyon, Lyon, France, ³Pediatric Rheumatology, CHU lyon, Hospices Civils de Lyon, HFME, lyon, France, ⁴Hopital Necker-Enfants Malades, Paris, France, ⁵cepidc, paris, France, ⁶Nephrology, Aix-Marseille Université - APHM, Marseille, France
Background/Purpose: Although regarded as a disease of adulthood, SLE is also seen in children, and is associated with an increased risk for aggressive clinical course…
Abstract Number: 2900 • 2015 ACR/ARHP Annual Meeting
Phospholipase A2 Receptor 1 Antibody in Membranous Lupus Nephritis
Amy Sandford¹, Malvika Gulati², Ademola Oliatan³, Angela Pakozdi², Ravindra Rajakariar⁴, Andrea Cove-Smith⁴ and Dev Pyne², ¹Barts Health NHS trust, London, United Kingdom, ²Rheumatology, Barts Health NHS Trust, London, United Kingdom, ³Barts Health NHS Trust, London, United Kingdom, ⁴Renal Medicine, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Recently phospholipase A2 receptor 1 (PLA2R1) has been found to be the antigenic target for primary membranous nephropathy (pMN) (1). Circulating anti-PLA2R1 autoantibody can…
Abstract Number: 2901 • 2015 ACR/ARHP Annual Meeting
Anti-dsDNA Antibodies Measured By Chemiluminescent Immunoassay Show Strong Association with Active Lupus Nephritis
Gabriella Lakos¹, John G. Hanly², Peter Martis¹, Chelsea Bentow¹, Milagros Garcia³, Odette Viñas³, Gerard Espinosa⁴, Ricard Cervera⁴ and Michael Mahler⁵, ¹Research, Inova Diagnostics, San Diego, CA, ²Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ³Immunology, Hospital Clinic of Barcelona, Barcelona, Spain, ⁴Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain, ⁵Inova Diagnostics, San Diego, CA
Background/Purpose: Anti-dsDNA antibodies support the diagnosis of systemic lupus erythematosus (SLE), and their quantification is useful for the assessment of lupus nephritis (LN) and the…
Abstract Number: 2902 • 2015 ACR/ARHP Annual Meeting
The Initial Presentation of Cerebrovascular Disease Attributed to Lupus Is Most Frequent Early in the Disease Course: Results from an International, Inception Cohort Study
John G. Hanly¹, Qiuju Li², Li Su³, Murray Urowitz^4,5, Juanita Romero-Diaz⁶, C. Gordon⁷, Sang-Cheol Bae⁸, Sasha R Bernatsky⁹, Ann Clarke¹⁰, Daniel J Wallace¹¹, Joan T. Merrill¹², David A. Isenberg¹³, Anisur Rahman¹⁴, Ellen M. Ginzler¹⁵, Michelle Petri¹⁶, Ian N. Bruce¹⁷, Mary Anne Dooley¹⁸, Paul Fortin¹⁹, Dafna D. Gladman²⁰, Jorge Sanchez-Guerrero²¹, Kristján Steinsson²², Rosalind Ramsey-Goldman²³, Munther Khamashta²⁴, Cynthia Aranow²⁵, Graciela S. Alarcon²⁶, Barri J. Fessler²⁷, Susan Manzi²⁸, Ola Nived²⁹, Gunnar K. Sturfelt³⁰, Asad Zoma³¹, Ronald F. van Vollenhoven³², Manuel Ramos-Casals³³, Guillermo Ruiz-Irastorza³⁴, S. Sam Lim³⁵, Kenneth C. Kalunian³⁶, Murat Inanc³⁷, Diane L. Kamen³⁸, Christine A. Peschken³⁹, Søren Jacobsen⁴⁰, Anca Askanase⁴¹, Chris Theriault⁴² and Vernon Farewell⁴³, ¹Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ²MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, ³Nova Scotia Rehab Site, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ⁴Rheumatology, TWH, Toronto, ON, Canada, ⁵Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁷School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁸Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁹Division of Rheumatolog, McGill Unversity Health Cener, Montreal, QC, Canada, ¹⁰Division of Rheumatology, Department of Medicine, University of Calgary, Calgary, AB, Canada, ¹¹Cedars-Sinai Medical Center, West Hollywood, CA, ¹²Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹⁴Centre for Rheumatology Research, U College of London, London, United Kingdom, ¹⁵Medicine/Box 42, SUNY-Downstate, Brooklyn, NY, ¹⁶Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ¹⁷Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ¹⁸UNC Kidney Centre, Chapel Hill, NC, ¹⁹Medicine, Division of Rheumatology, Centre Hospitalier Universitaire de Quebec et Universite Laval, Quebec, QC, Canada, ²⁰Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²¹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²²Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²³Northwestern University Feinberg School of Medicine, Chicago, IL, ²⁴Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ²⁵Feinstein Institute for Medical Research, Manhasset, NY, ²⁶Medicine, University of Alabama at Birmingham, Birmingham, AL, ²⁷UAB, Birmingham, AL, ²⁸Rheumatology, Allegheny Health Network, Pittsburgh, PA, ²⁹Rheumatology, Inst of Clinical sciences, Lund, Sweden, ³⁰Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ³¹Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ³²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³³Autoimmune Diseases, IDIBAPS, Hospital Clinic, Barcelona, Spain, ³⁴Universidad del Pais Vasco, Servicio de Medicina Interna, Hospital de Cruces, Bizkaia, Spain, ³⁵Emory University School of Medicine, Atlanta, GA, ³⁶Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³⁷Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁸Medicine, Medical University of South Carolina, Charleston, SC, ³⁹Rheumatology, Univ of Manitoba, Winnipeg, MB, Canada, ⁴⁰Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁴¹Columbia University College of Physicians & Surgeons, New York, NY, ⁴²Dept of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁴³Medicine, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Neuropsychiatric (NP) disease in patients with SLE includes cerebrovascular events. We determined the frequency, characteristics and attribution in a large, multi-ethnic/racial, inception cohort of…
Abstract Number: 2903 • 2015 ACR/ARHP Annual Meeting
Late-Onset Neutropenia Following Rituximab Treatment in Patients with Systemic Lupus Erythematosus
Ioannis Parodis, Frida Söder, Ronald F. van Vollenhoven, Elisabet Svenungsson and Iva Gunnarsson, Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The incidence and clinical consequences of rituximab-mediated late-onset neutropenia (LON) have been studied in various diseases, but data from Systemic Lupus Erythematosus (SLE) are…
Abstract Number: 2904 • 2015 ACR/ARHP Annual Meeting
Utility of Untimed Single Urine Protein/Creatinine Ratio As a Substitute for the 24 Hour Proteinuria for the Assessment of Proteinuria in Systemic Lupus Erythematosus
Jorge Medina-Rosas¹, Dafna Gladman², Jiandong Su², Arthy Sabapathy³ and Murray Urowitz^2,4, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: To determine the utility of an untimed Sample of Urine Protein/Creatinine ratio (S-UPCR) as a screening test for proteinuria and its ability to accurately…
Abstract Number: 2905 • 2015 ACR/ARHP Annual Meeting
Urinary Protein:Urinary Creatinine Ratio in an Untimed Urine Specimen and Estimated Glomerular Filtration Rate Are Reliable Measures of Proteinuria and Renal Function in Patients with Lupus Nephritis
Yasuhiro Katsumata, Hirokazu Nishina, Masanori Hanaoka, Yasushi Kawaguchi, Kae Takagi, Akiko Tochimoto, Yuki Ichimura and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Renal Disease Subcommittee of the American College of Rheumatology (ACR) Ad Hoc Committee on Systemic Lupus Erythematosus (SLE) has recommended the urinary protein level…
Abstract Number: 2906 • 2015 ACR/ARHP Annual Meeting
Can Immunosuppressive Drug Treatment Reduce Mortality in Patients with Systemic Lupus Erythematosus (SLE): A Propensity Score Analysis of a Longitudinal Cohort of 803 Patients?
Chi Chiu Mok¹, Sau Mei Tse¹ and Ling Yin Ho², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: To evaluate the association of the use of immunosuppressive agents and mortality in a longitudinal cohort of SLE patientsMethods: Patients who fulfilled >=4 1997 ACR…
Abstract Number: 2907 • 2015 ACR/ARHP Annual Meeting
The Natural History of Thrombotic Events in Systemic Lupus Erythematosus and Associated Risk Factors
Katharine Hickman¹, Laurence S Magder² and Michelle Petri³, ¹University College London, London, United Kingdom, ²University of Maryland School of Medicine, Baltimore, MD, ³Rheumatology, Johns Hopkins University Hospital, Baltimore, MD
Background/Purpose: Prospective cohort studies of the natural history of thrombosis in SLE, including events before diagnosis are rare. No previous study has identified risk factors…
Abstract Number: 2908 • 2015 ACR/ARHP Annual Meeting
Diagnostic and Screening Accuracy of Spot Urinary Protein-Creatinine Ratio Compared to Protein Content in a 24 Hour-Urine Collection in Systemic Lupus Erythematosus: Systematic Review and Meta-Analysis
Jorge Medina-Rosas¹, Kristy Yap², Melanie Anderson³, Jiandong Su² and Zahi Touma², ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Library and Information Services, University Health Network, University Health Network, Toronto, ON, Canada
Background/Purpose: To systematically review literature on the utility of spot urinary protein-creatinine ratio (PCR) as a screening test for proteinuria and its ability to accurately…
Abstract Number: 2909 • 2015 ACR/ARHP Annual Meeting
A Systematic Review and Meta-Analysis of Cutaneous Manifestations in Late Versus Early-Onset Systemic Lupus Erythematosus
Jennifer Medlin¹, Karen E. Hansen², Sara Fitz³ and Christie M. Bartels⁴, ¹Internal Medicine, University of Wisconsin Hospitals and Clinics, Madison, WI, ²Rheumatology/Medicine, Univ of Wisconsin, Madison, WI, ³Department of Dermatology, Mercy Medical Center, Dubuque, IA, ⁴Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Systemic lupus erythematosus (SLE) is commonly diagnosed in females of reproductive age, with those diagnosed after the age of 50 referred to as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].